Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib-Reference-Cited by-同舟云学术

Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib

Published:2019-06 Issue:6 Volume:14 Page:e115-e117
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Qin Bao-Dong,Jiao Xiao-Dong,Liu Ke,Wu Ying,Zang Yuan-Sheng

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference4 articles.

1. A novel EML6-ALK FBXO11-ALK double fusion variant in lung adenocarcinoma and response to crizotinib;Lin;J Thorac Oncol,2018

2. Reporting on two novel fusions, DYSF-ALK and ITGAV-ALK, coexisting in one patient with adenocarcinoma of lung, sensitive to crizotinib;Yin;J Thorac Oncol,2018

3. Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patient;Tian;Eur Respir J,2017

4. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants;Li;Lung Cancer,2018

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review;Discover Oncology;2024-02-20

2. Coexistence of a novel SRBD1-ALK, ALK-CACNA1D double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report;Heliyon;2024-01

3. Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report;Discover Oncology;2023-04-13

4. Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer;Current Oncology;2022-10-16

5. Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively;Diagnostic Pathology;2022-02-10